Diabetic Neuropathy: Current Treatments and the Potential of Scrambler Therapy

Diabetic Neuropathy: Current Treatments and the Potential of Scrambler Therapy

Diabetic neuropathy (DN) is a prevalent and debilitating complication of diabetes mellitus (DM), characterized by nerve damage that leads to a variety of symptoms. It significantly impacts the quality of life for those affected, increasing the risk of foot ulcers and other complications. Given its high prevalence and the limitations of current treatments, there is a pressing need for more effective therapies (Abd-Elsayed, Schiavoni, & Sachdeva, 2016; Boyle et al., 2014; Christo, Kamson, & Smith, 2020).

Understanding Diabetic Neuropathy

Prevalence and Impact: DN is a common complication of diabetes, with a significant number of individuals with serious illnesses also suffering from diabetes as a comorbidity (Finsterer & Scorza, 2022). It is characterized by nerve damage, most commonly affecting the feet (Finsterer & Scorza, 2022; Ghatak et al., 2011).

Symptoms: Patients typically experience symptoms such as numbness, burning, tingling, and pain, often described as electric shocks (Boyle et al., 2014; D’Amato et al., 2018). These symptoms can significantly impair daily activities and overall well-being (D’Amato et al., 2018; Hahck Soo Park et al., 2017).

Risk Factors: Inadequately treated diabetic peripheral neuropathy elevates the risk of foot ulcer formation, potentially leading to more severe complications (Slangen et al., 2014).

Diagnosis: An electromyogram is typically used to diagnose diabetic neuropathy.

Challenges in Treatment: The neuropathic pain associated with DN is often resistant to conventional pharmaceutical interventions (Boyle et al., 2014; Trivedi, Silvestri, & Wolfe, 2013).

Current Treatments for Diabetic Neuropathy and Their Limitations

Several conventional treatments are available for managing DN, but they often come with limitations, including side effects and limited efficacy.

Medications:

• Antidepressants, Anticonvulsants, and Opiate Analgesics: These are commonly used as first- and second-line treatments for neuropathic pain (Boyle et al., 2014). However, they often produce significant side effects and may not provide substantial relief (Boyle et al., 2014).
• Pregabalin and Gabapentin: Often recommended as first-line medications (Boyle et al., 2014), yet they may also present tolerability issues and limited effectiveness for some patients (Trivedi et al., 2013).
• Opioid-like Medications: Tramadol and tapentadol, as well as topical agents like lidocaine patches and capsaicin cream, may be considered (Boyle et al., 2014), but their efficacy varies, and side effects can be problematic (Boyle et al., 2014).
• Spinal Cord Stimulation (SCS): While highly effective for DN, SCS is an invasive and expensive option, posing risks such as infection and spinal fluid leakage (Slangen et al., 2014).
• Transcutaneous Electrical Nerve Stimulation (TENS): TENS may provide relief for some patients (Walsh et al., 2009). However, its effectiveness is not definitively established without larger, placebo-controlled clinical trials (Johnson et al., 2022; Walsh et al., 2009).

Lifestyle Modifications:

• Glycemic Control: Evidence suggests that improved glycemic control, through diet and exercise, may reduce the progression of neuropathy or possibly even result in the regrowth of epidermal nerve fibers (Jin et al., 2010).
• Aerobic Exercise: Regular physical activity can improve peripheral nerve functions in type 2 diabetes mellitus (Jin et al., 2010).

Scrambler Therapy: A Promising Alternative

Scrambler Therapy has emerged as a non-invasive neuromodulation technique that may offer significant benefits in alleviating the symptoms of DN (Loprinzi et al., 2020; Marineo et al., 2012).

Mechanism of Action: Scrambler Therapy is a cutaneous electrostimulation method approved by the FDA for neuromodulation of pain (Christo et al., 2020; Marineo et al., 2012). It involves the application of non-invasive electrodes to the skin around the painful areas, delivering synthetic “non-pain” information via cutaneous nerves to “scramble” afferent pain signals (Smith et al., 2017).

Application and Procedure:

• Electrodes are positioned in areas where there is no pain to maximize effectiveness (Smith et al., 2010).
• The electrical stimulus is gradually increased to the maximum value tolerated by the patient (Smith et al., 2010).
• Treatment sessions typically last 45 minutes and are administered several times a week over multiple weeks (Smith et al., 2010).

Efficacy in Clinical Trials:

Scrambler Therapy has been applied to manage various chronic neuropathic pain conditions, including cancer and non-cancer pain, as well as numbness and tingling (Marineo et al., 2012; Smith et al., 2017). A case report demonstrated successful use of Scrambler Therapy in treating a patient with diabetic peripheral neuropathy, where typical neuropathic pain medications had failed (Smith et al., 2010). The patient’s NRS score decreased from 6/10 to 3/10 after the first Scrambler Therapy session, and after 10 sessions, the patient reported an NRS score of 2/10 for bilateral plantar foot pain (Smith et al., 2010).

Scrambler Therapy has demonstrated success in randomized controlled trials for conditions such as low-back pain, spinal cord stenosis, postherpetic neuropathy, chemotherapy-induced neuropathy, and neuromyelitis optica spectrum disorder (Loprinzi et al., 2020; Mealy et al., 2020).

Advantages Over Traditional Methods:

• Non-Invasive: Scrambler Therapy is a non-invasive treatment, reducing the risks associated with surgical interventions like spinal cord stimulation (Loprinzi et al., 2020).
• Reduced Side Effects: Unlike many pharmacological treatments, Scrambler Therapy is associated with minimal side effects, improving patient tolerability and adherence (Smith et al., 2017).
• Potential for Long-Term Relief: Scrambler Therapy has shown potential for providing lasting pain relief, with some patients experiencing benefits lasting for weeks or months after treatment (Smith et al., 2020).
• Integration with Glycemic Control and Lifestyle Modifications: To maximize the therapeutic effect of Scrambler Therapy in patients with diabetic peripheral neuropathy, it is important to perform glycemic control and manage lifestyle modifications such as aerobic exercise (Jin et al., 2010).

Case Studies and Clinical Evidence

Successful Use in Diabetic Peripheral Neuropathy: A 45-year-old female patient with diabetes mellitus was referred with bilateral plantar foot pain, which she described as tingling and resembling the sensation of heat. After 10 Scrambler Therapy sessions, the patient reported an NRS score of 2/10 for bilateral plantar foot pain, highlighting Scrambler Therapy’s potential to alleviate neuropathic pain related to DM (Smith et al., 2010).

Summary:

Comparing the different treatments for Diabetic Neuropathy (DN), including their effectiveness, invasiveness, side effects, and benefits:

Notes:

• Medications like antidepressants, anticonvulsants, and opioids are common first- and second-line treatments but often come with significant side effects, and their efficacy varies.
• Spinal Cord Stimulation (SCS) is highly effective but comes with risks due to its invasive nature, making it less desirable as a first-line option.
• Scrambler Therapy is a promising, non-invasive treatment that offers lasting pain relief with minimal side effects, making it an attractive option for many patients.
• Glycemic control and exercise offer foundational benefits in managing diabetic neuropathy but might not provide immediate relief from pain.

Diabetic neuropathy remains a significant challenge in diabetes management, with many patients experiencing inadequate relief from current treatments (Boyle et al., 2014). Scrambler Therapy presents a promising non-invasive alternative that has shown potential in alleviating neuropathic pain associated with DN (Smith et al., 2020). By delivering “non-pain” signals through cutaneous nerves, Scrambler Therapy may modulate central sensitization and provide lasting relief (Smith et al., 2017). While more rigorous, high-quality clinical trials are needed, the existing evidence suggests that Scrambler Therapy could become an integral part of a comprehensive approach to managing diabetic neuropathy, improving the quality of life for millions affected by this condition (Smith et al., 2020; Tovar Sanchez & Smith, 2024).

References

Abd-Elsayed, A., Schiavoni, N., & Sachdeva, H. (2016). Efficacy of spinal cord stimulators in treating peripheral neuropathy: a case series. Journal of Clinical Anesthesia, 28, 74–77.

Boyle, Y., Fernando, D., Kurz, H., et al. (2014). The effect of a combination of gabapentin and donepezil in an experimental pain model in healthy volunteers: results of a randomized controlled trial. Pain, 155(12), 2510-2516.

Christo, P. J., Kamson, D. O., & Smith, T. J. (2020). Treatment of Dérien–Roussy syndrome pain with Scrambler therapy. Pain Management, 10(3), 141-145.

Coyne, P. J., Wan, W., Dodson, P., Swainey, C., & Smith, T. J. (2013). A trial of Scrambler therapy in the treatment of cancer pain syndromes and chronic chemotherapy-induced peripheral neuropathy. Journal of Pain and Palliative Care Pharmacotherapy, 27(4), 359-364.

D’Amato, S. J., Mealy, M. A., Erdek, M. A., Kozachik, S., & Smith, T. J. (2018). Scrambler therapy for the treatment of chronic central pain: a case report. A & A practice, 10(12), 313-315.

Finsterer, J., & Scorza, F. A. (2022). Small fiber neuropathy. Acta Neurologica Scandinavica, 145(5), 493-503.

Ghatak, R. K., Nandi, S. N., Bhakta, A., Mandal, G. C., Bandyopadhyay, M., & Kumar, S. (2011). Prospective study of application of biological communication (cybernetics) in management of chronic low back pain—a preliminary report. Nepal Medical College Journal, 13(4), 257-260.